Acquisition from Neuropore Therapies Bolsters GCT’s Arsenal Against Devastating Brain and Breast Cancers
San Diego, CA, March 6, 2025 – Global Cancer Technology, Inc. (GCT), a pre-clinical stage biopharma company, has acquired full ownership of intellectual property for two potentially life-saving cancer treatments from Neuropore Therapies. This strategic move significantly strengthens GCT’s portfolio in the fight against aggressive cancers, including glioblastoma and drug-resistant breast cancer.
The acquisition includes GCT-007, a unique PI3K inhibitor capable of crossing the blood-brain barrier, and GCT-008, a promising VPS34 inhibitor. Both assets show immense potential in tackling some of the most challenging forms of cancer.
“This acquisition is a game-changer for GCT and, more importantly, for patients battling these devastating diseases,” said John Clark, CEO of Global Cancer Technology. “By securing full ownership of these patents, we’ve removed financial barriers and accelerated our path to bringing these potentially life-saving treatments to those who need them most.”
Mark Yung, executive chairman of Neuropore Therapies, added, “We’re excited to see GCT drive forward with these therapies, addressing critical unmet needs in brain and breast cancer treatment.”
GCT is currently offering pre-IPO shares to accredited investors to support the development of breakthrough pre-clinical data, paving the way for a phase I clinical trial in glioblastoma.
About Compound GCT-007
GCT-007 is a unique small molecule PI3Kinase inhibitor drug that targets both the PI3K and autophagy pathways. Preclinical studies have shown it to effectively reduce cell growth and increase immune recognition in various cancer cell types. The Company is currently focused on developing the drug for the treatment of glioblastoma, diffuse midline glioma, and drug-resistant breast cancer. The Company intends to file an Investigational New Drug (IND) application with the US Food and Drug Administration to enter a Phase 1 clinical trial for glioblastoma.
About Global Cancer Technology
Global Cancer Technology (GCT) is an emerging biopharmaceutical company focused on developing novel treatments for cancer, particularly in the domain of glioblastoma therapy. The company’s main offering includes a small molecule PI3K inhibitor capable of crossing the blood-brain barrier, which has demonstrated potential in preclinical studies. GCT holds numerous patents and other assets, including licenses to commercialize nanoparticle technology for the treatment of cancer and other diseases requiring targeted therapeutic delivery. In collaboration with highly acclaimed academic institutions such as UCSD and the University of Washington, along with recognized industry leaders, GCT aims to make these innovative therapies available to patients as quickly as possible.
About Neuropore Therapies
Neuropore Therapies, Inc. is a San Diego, California-based biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company’s approaches target core pathological processes underlying these disorders, including intracellular accumulation of neurotoxic misfolded proteins and neuroinflammation. Neuropore Therapies is advancing several preclinical stage compounds with complementary mechanisms of action, aiming to enhance the clearance of proteins that have already formed toxic aggregates and mitigate their toxic neuroinflammatory actions.
For more information about Global Cancer Technology or to request an interview with John Clark, please contact David Jones [david@globalcancertechnology.co].
Statements in this news release may contain forward–looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company’s most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized
